TLDR: South Korea put the world’s first dedicated law for digital medical products into force in 2025, creating a purpose-built path for artificial intelligence (AI) software, digital therapeutics, and connected health tools. By treating fast-moving software on its own terms, including pre-approved updates for AI, Korea turned regulatory clarity into a competitive advantage. For corporates building in regulated markets, it offers both a live market and a template worth studying.
A software-first law
Most countries regulate digital health by stretching rules written for physical medical devices. Korea took a different route. Its Digital Medical Products Act, known as the DMPA, stands as the first comprehensive law focused solely on digital medical products. The legislation passed in January 2024, and most provisions took effect in January 2025.
The act sorts digital health into clear categories, covering digital medical devices, combination products, and digital support tools. That structure gives developers, hospitals, and investors a shared vocabulary and a predictable process, which lowers the uncertainty that slows adoption in markets governed by improvised rules.
Pre-approved AI updates address the hardest problem
The most forward-looking element tackles the central challenge of medical AI: software that learns and improves. Traditional device regulation treats every change as a new product requiring fresh review, which sits awkwardly with models designed to update. Korea built a path for pre-approved AI software updates, and its regulator has issued detailed guidance on AI-applied medical devices.
This matters because it lets approved AI products evolve within an agreed framework. A developer gains a route to keep a model current while preserving safety oversight, which supports both clinical performance and patient confidence. Other regulators studying the same problem now have a working reference to learn from.
Clear rules pull products to market
Regulatory clarity tends to attract the products that need it most. The wider Digital Health Market Scan noted Korea advancing approvals for digital therapeutics (DTx), including an insomnia treatment among the first cleared under the new regime. Each early approval validates the pathway and signals to founders and corporates that Korea offers a serious, navigable market.
That momentum compounds. As approvals accumulate, clinicians gain confidence, payers gain precedent, and the next wave of developers gains a proven route to follow. A clear rulebook becomes a magnet for the talent and capital that build the category.
The lesson for regulated-industry innovators
Korea’s example reframes how to think about regulation. A purpose-built framework can act as an accelerant, giving innovators the certainty they need to invest, build, and launch. Companies that learn to operate inside such frameworks, and that engage regulators early, gain a head start that competitors struggle to close.
The practical takeaways travel well beyond Korea. Treat regulatory strategy as a core part of product design. Map the approval path before building. Watch the markets that write clear rules first, because they often preview where global standards land. The countries that make digital medicine legible will host the companies that scale it.
Where this connects to building in regulated markets
For corporates seeking to innovate in healthcare, the message is encouraging. The barrier is becoming a navigable process, and the markets that lead on clarity reward those who move early and thoughtfully. Success calls for a blend of clinical evidence, regulatory fluency, and disciplined execution.
That blend defines the work of the 9 Months Later programme, which helps organisations in regulated industries turn promising ideas into validated, market-ready products. Korea wrote the first rulebook for digital medicine. The companies that read it closely will shape what comes next.
References
- Korea enacts the Digital Medical Products Act (DMPA): https://www.qualtechs.com/en-gb/article/korea-digital-medical-products-act-march-2025
- South Korea issues more guidelines on AI-applied medical products: https://www.mlex.com/mlex/articles/2408170/south-korea-issues-more-guidelines-on-ai-applied-medical-products
- Digital Health Market Scan, 170th Edition, April 2025 (Marc Sluijs): https://digitalhealth.network
